Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fi

Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage

Related Keywords

Fred Ahlholm , Helen Shik , Remy Luthringer , Minerva Neurosciences , Company Expects To Submit , Shik Communications , Drug Administration , Minerva Neurosciences Inc , Nasdaq , Company Expects , Third Quarter , Drug Administrationon April , Executive Chairman , Chief Executive Officer , Interest Expense , Future Royalties , Royalty Pharma , Private Securities Litigation Reform Act , Term Liabilities , Months Ended March , Aminerva , Neurosciences , Reports , First , Quarter , 022 , Financial , Results , Business , Updates ,